Patents Examined by Hankyel T. Park
  • Methods for HIV sequencing and genotyping
    Patent number: 6379957
    Abstract: Methods are provided for amplifying regions of the HIV pol gene amplifying double-stranded nucleic acid template derived from HIV tube RT-PCR with novel PCR primers to produce amplified target sequences. Methods are also provided for analyzing the nucleotide sequence of these amplified targets using novel sequencing primers and the data is analyzed. The determined nucleotide sequence can be compared to the sequence of known drug resistance mutations in the HIV pol gene to determine the viral genotype.
    Type: Grant
    Filed: September 21, 1998
    Date of Patent: April 30, 2002
    Inventors: Leslie A. Johnston-Dow, Lisa Demeter, Camille B. White, Keming Song, Robert Kohlenberger, Morgan Conrad, Angela Myers
  • Proteins related to encapsulation and genes encoding the same
    Patent number: 6376658
    Abstract: The present invention relates to a protein related to encapsulation in immune reaction and a gene encoding the same.
    Type: Grant
    Filed: March 9, 2000
    Date of Patent: April 23, 2002
    Assignee: Samyang Genex Corporation
    Inventors: Bok Luel Lee, Mi Young Cho, Chong Jin Park, Seung-Suh Hong, Hyun-Soo Lee
  • Recombinant vaccinia viral vectors
    Patent number: 6372455
    Abstract: The present invention provides recombinant vaccinia virus in which the E3L gene is replaced by a gene encoding an E3L homolog from the orf virus. Compositions comprising the recombinant vaccinia virus and methods of use thereof are also provided.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: April 16, 2002
    Assignee: Arizona Board of Regents
    Inventors: Bertram Jacobs, Jeffrey Langland, Sangeetha Vijaysri
  • Vaginal lactobacillus medicant
    Patent number: 6372209
    Abstract: Disclosed are novel isolated strains of bacteria of the genus Lactobacillus which are useful in a vaginal medicant. Also disclosed are medicants containing such Lactobacilli, a novel preservation matrix for microorganisms, a method for preserving microbial cells within a medicant, and methods for preventing and treating vaginal and gastrointestinal infections.
    Type: Grant
    Filed: January 5, 2000
    Date of Patent: April 16, 2002
    Assignee: Gyne Logix, Inc.
    Inventor: Gerald L. Chrisope
  • Metal organothiol particles
    Patent number: 6369206
    Abstract: Novel metal-lipid molecules have the formula M—Or—L. M represents a cluster or colloid of atoms of Au, Ag, Pt, Pd, or combinations thereof. Or is an organic group covalently attached to the metal atoms. L represents a lipid moiety. In a preferred embodiment, M represents a cluster of about 50-70 gold atoms having a diameter of about 1.4 nm in diameter and L represents dipalmitoyl phosphatidyl ethanolamine.
    Type: Grant
    Filed: July 19, 2000
    Date of Patent: April 9, 2002
    Inventors: Robert D. Leone, James F. Hainfeld
  • Hematopoietic cell method for treatment of HIV infection
    Patent number: 6365404
    Abstract: The risk of drug resistance in HIV infection is reduced by profoundly suppressing the viral load using novel hematopoietic cells. Modified CD4 lymphocyte host cells are used to “capture” virons in a sterile micro-environment. The host's CD4 T-cell lymphocytes are replaced with lymphocytes derived from autologous or homologous stem cells which do not express the CKR-5 receptor, further inhibiting viral load.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: April 2, 2002
    Inventor: Francis E. O'Donnell, Jr.
  • SNF2 related CBP activator protein (SRCAP)
    Patent number: 6365372
    Abstract: A protein, SRCAP, is provided. The protein is capable of co-activating CREB binding protein (CBP) mediated transcription, as well as activating transcription without CBP. SRCAP is a Snf2 family member. As such, it has ATPase activity. Fragments of SRCAP are also provided, as are polynucleotides encoding SRCAP and its fragments. Antibodies that bind to SRCAP are also provided. These compositions are useful for enhancing transcription in cells and patients. The compositions are also useful for reducing transcription in cells and patients.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: April 2, 2002
    Assignee: Saint Louis University
    Inventors: John Chrivia, Peter Yaciuk
  • Exonuclease-mediated nucleic acid reassembly in directed evolution
    Patent number: 6361974
    Abstract: This invention provides methods of obtaining novel polynucleotides and encoded polypeptides by the use of non-stochastic methods of directed evolution (DirectEvolution™). A particular advantage of exonuclease-mediated reassembly methods is the ability to reassemble nucleic acid strands that would otherwise be problematic to chimerize. Exonuclease-mediated reassembly methods can be used in combination with other mutagenesis methods provided herein. These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis™) and non-stochastic polynucleotide reassembly (GeneReassembly™). This invention provides methods of obtaining novel enzymes that have optimized physical &/or biological properties. Through use of the claimed methods, genetic vaccines, enzymes, small molecules, and other desirable molecules can be evolved towards desirable properties.
    Type: Grant
    Filed: March 27, 2000
    Date of Patent: March 26, 2002
    Assignee: Diversa Corporation
    Inventors: Jay M. Short, Tsotne David Djavakhishvili, Gerhard Johann Frey
  • Methods of treatment of eye trauma and disorders
    Patent number: 6358696
    Abstract: Methods are provided for treatment of eye disorders and injury, including methods for treatment of reduced flow of blood or other nutrients to retinal tissue and/or optic nerve, methods for treatment of retinal ischemia and trauma and methods for treatment for optic nerve injury/damage.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: March 19, 2002
    Inventor: Robert N. McBurney
  • End selection in directed evolution
    Patent number: 6358709
    Abstract: This invention provides methods of obtaining novel polynucleotides and encoded polypeptides by the use of non-stochastic methods of directed evolution (DirectEvolution™). A particular advantage of end-selection-based methods is the ability to recover full-length polynucleotides from a library of progeny molecules generated by mutagenesis methods. These methods include non-stochastic polynucleotide site-saturation mutagenesis (Gene Site Saturation Mutagenesis™) and non-stochastic polynucleotide reassembly (GeneReassembly™). This invention provides methods of obtaining novel enzymes that have optimized physical &/or biological properties. Through use of the claimed methods, genetic vaccines, enzymes, small molecules, and other desirable molecules can be evolved towards desirable properties. For example, vaccine vectors can be obtained that exhibit increased efficacy for use as genetic vaccines.
    Type: Grant
    Filed: March 9, 2000
    Date of Patent: March 19, 2002
    Assignee: Diversa Corporation
    Inventors: Jay M. Short, Gerhard Johann Frey
  • Feline calicivirus isolated from cat urine and vaccines thereof
    Patent number: 6355246
    Abstract: The present invention provides an isolated feline calicivirus and mutants thereof, which were isolated from the urine of a cat with lower urinary tract disorder. The present invention further provides nucleic acid clones of the virus, in particular, a clone which encodes the capsid antigen of the virus. The present invention is useful for providing a live or killed virus vaccine comprising the virus or mutants thereof, a subunit vaccine comprising the capsid antigen of the virus, a nucleic acid vaccine encoding the capsid antigen of the virus, and a recombinant virus vector vaccine encoding the capsid antigen of the virus. The present invention also provides a method for isolating feline calicivirus from urine and an assay for diagnosing cats infected with feline calicivirus.
    Type: Grant
    Filed: June 8, 2000
    Date of Patent: March 12, 2002
    Assignee: Board of Trustees of Michigan State University
    Inventors: John M. Kruger, Roger K. Maes, Aivars Vilnis
  • Exonucease-mediated gene assembly in directed evolution
    Patent number: 6352842
    Abstract: A directed evolution process comprising novel methods for generating improved progeny molecules having desirable properties, including, for example, a method for rapid and facilitated production from a parental polynucleotide template, of a set of mutagenized progeny polynucleotides wherein at least one codon encoding each of the 20 naturally encoded amino acids is represented at each original codon position. This method, termed site-saturation mutagenesis, or simply saturation mutagenesis, is preferably based on the use of the degenerate N,N,G/T sequence. Also, a method of producing from a parental polypeptide template, a set of mutagenized progeny polypeptides wherein each of the 20 naturally encoded amino acids is represented at each original amino acid position.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: March 5, 2002
    Assignee: Diversa Corporation
    Inventors: Jay M. Short, Gerhard J. Frey, Tsotne D. Djavakhishvili
  • Dirofilaria and brugia thioredoxin peroxidase type-2 proteins and uses thereof
    Patent number: 6352836
    Abstract: The present invention relates to: Dirofilaria and Brugia thioredoxin peroxidase type-2 (TPx-2) proteins; Dirofilaria and Brugia TPx-2 nucleic acid molecules, including those that encode such TPx-2 proteins; antibodies raised against such TPx-2 proteins; and compounds that inhibit Dirofilaria and Brugia TPx-2 activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic helminths.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: March 5, 2002
    Assignee: Heska Corporation and Colorado State University Research Foundation
    Inventors: Ramaswamy Chandrashekar, Naotoshi Tsuji
  • Isolated 55 to 72 kDa protein which binds to prion proteins
    Patent number: 6350854
    Abstract: The invention involves an isolated anti-prion-protein binding protein that has a molecular weight of about 55 kD to about 72 kD as determined by SDS-PAGE. Also described is a peptide derived from this isolated anti-prion-protein binding protein. Diagnostic uses for each of these molecules are discussed.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: February 26, 2002
    Assignees: Ludwig Institute for Cancer Research, Fundacao Antonio Prudente
    Inventors: Ricardo R. Brentani, Vilma J. Martins, Sandro J. de Souza
  • Antigen test to detect equine protozoal myeloencephalitis in horse serum and cerebrospinal fluid
    Patent number: 6344337
    Abstract: The present invention provides an immunoassay to detect identifying antigens in horses that are infected with Sarcocystis neurona. The immunoassay is preferably an antigen-capture-based assay that relies upon polyclonal or monoclonal antibodies against a 16 (±4) and/or 30 (±4) kDa antigens specific to Sarcocystis neurona to detect the presence of the 16 (±4) and/or 30 (±4) kDa antigens in equine serum or equine cerebrospinal fluid.
    Type: Grant
    Filed: February 18, 2000
    Date of Patent: February 5, 2002
    Assignee: Board of Trustees of Michigan State University
    Inventors: Linda S. Mansfield, Mary G. Rossano, Alice J. Murphy, Ruth A. Vrable
  • Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates and uses thereof
    Patent number: 6342586
    Abstract: This invention provides an immunoconjugate which comprises 1) a non-peptidyl toxin and 2) a CD4-gamma2 chimeric heavy chain homodimer linked thereto. This invention also provides an immunoconjugate which comprises 1) a gamma radiation-emitting radionuclide of low to moderate cytotoxicity and 2) a CD4-gamma2 chimeric heavy chain homodimer linked thereto. This invention further provides an immunoconjugate which comprises 1) a non-peptidyl toxin and 2) a heterotetramer comprising two heavy chains and two light chains, both heavy chains being either 1) IgG2 heavy chains or b) chimeric CD4-IgG2 heavy chains, and both light chains being either a) kappa light chains or b) chimeric CD4-kappa light chains.
    Type: Grant
    Filed: September 29, 1999
    Date of Patent: January 29, 2002
    Assignee: Progenics Pharmaceuticals, Inc.
    Inventors: Graham P. Allaway, Paul J. Maddon
  • Protein fragments for use in protein targeting
    Patent number: 6340577
    Abstract: A protein is described. The protein comprises a lipid globule targeting sequence linked to a protein of interest (POI) wherein the targeting sequence comprises a hepatitis C virus (HCV) core protein or fragment or homologue thereof.
    Type: Grant
    Filed: December 1, 1998
    Date of Patent: January 22, 2002
    Assignee: Medical Research Council
    Inventors: Ralph Graham Hope, John McLauchlan
  • Stress proteins and uses therefor
    Patent number: 6338952
    Abstract: The present invention relates to stress proteins and methods of modulating an individual's immune response. In particular, it relates to the use of such stress proteins in immune therapy and prophylaxis, which results in an induction or enhancement of an individual's immune response and as an immunotherapeutic agent which results in a decrease of an individual's immune response to his or her own cells. The present invention also relates to compositions comprising a stress protein joined to another component, such as a fusion protein in which a stress protein is fused to an antigen. Further, the present invention relates to a method of generating antibodies to a substance using a conjugate comprised of a stress protein joined to the substance.
    Type: Grant
    Filed: November 3, 1994
    Date of Patent: January 15, 2002
    Assignee: Whitehead Institute for Biomedical Research
    Inventor: Richard A. Young
  • Use of a non-mammalian DNA virus to express an exogenous gene in a mammalian cell
    Patent number: 6338962
    Abstract: Disclosed are methods, nucleic acids, and cells for expressing an exogenous gene in a mammalian cell, involving introducing into the cell a non-mammalian DNA virus (e.g., a baculovirus) whose genome carries an exogenous gene, and growing the cell under conditions such that the gene is expressed. Also disclosed are methods for treating gene deficiency disorders, neurological disorders, or cancers in a mammal by providing to a cell a therapeutically effective amount of a virus whose genome carries an exogenous, therapeutic gene and growing the cell under conditions such that the exogenous gene is expressed in the mammal.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: January 15, 2002
    Assignee: The General Hospital Corporation
    Inventor: Frederick M. Boyce
  • Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
    Patent number: 6338963
    Abstract: Disclosed herein are methods directed generally to the control of neural activity and for selectively and controllably inducing the in vivo genetic expression of one or more naturally occurring genetically encoded molecules in mammals. More particularly, the present invention selectively activates or derepresses genes encoding for specific naturally occurring molecules such as neurotrophic factors through the administration of carbon monoxide dependent guanylyl cyclase modulating purine derivatives. The methods of the present invention may be used to affect a variety of cellular and neurological activities and to therapeutically or prophylactically treat a wide variety of neurodegenerative, neurological, and cellular disorders.
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: January 15, 2002
    Assignee: NeoTherapeutics, Inc.
    Inventors: Alvin J. Glasky, Michael P. Rathbone